ABBV - AbbVie Recent Insider Activity | Benzinga
Making a noteworthy insider sell on March 20, Jeffrey R. Stewart, EVP at AbbVie (NYSE:ABBV), is reported in the latest SEC filing.
What Happened: A Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday outlined that Stewart executed a sale of 58,949 shares of AbbVie with a total value of $10,539,508.
Monitoring the market, AbbVie's shares up by 0.57% at $177.27 during Thursday's morning.
Delving into AbbVie's Background
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
Understanding the Numbers: AbbVie's Finances
Decline in Revenue: Over the 3 months period, AbbVie faced challenges, resulting in a decline of approximately -5.42% in revenue growth as of 31 December, 2023. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care ...